Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | MKNK1 | Q9BUB5 | 7/20 | 0.50 |
| ▸ | LCK | P06239 | 3/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 5/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31722849 | 0.83 | POLB (0.70) | ROCK1POLBHTTMKNK1LCK | |
| SCHEMBL2147667 | 0.83 | POLB (0.70) | ROCK1POLBHTTMKNK1LCK | |
| SCHEMBL14525195 | 0.81 | ROCK1 (0.51) | ROCK1POLBHTTMKNK1LCK | |
| SCHEMBL31241183 | 0.81 | POLB (0.67) | ROCK1POLBHTTMKNK1LCK | |
| SCHEMBL4974842 | 0.78 | ROCK1 (0.51) | ROCK1POLBHTTMKNK1LCK | |
| SCHEMBL2186020 | 0.76 | CDC7 (0.54) | ROCK1HTTMKNK1MKNK2MAPT | |
| SCHEMBL11988769 | 0.76 | ALDH1A1 (0.47) | HTTMAPTRAB9A | |
| SCHEMBL4813477 | 0.76 | POLB (0.60) | ROCK1POLBHTTMKNK1LCK | |
| SCHEMBL16277601 | 0.76 | CYP1A2 (0.39) | ROCK1POLBHTTMKNK1LCK | |
| SCHEMBL17351699 | 0.75 | FGFR1 (0.62) | ROCK1POLBHTTMKNK1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2343285-B1 | Peptoid compounds useful as antibiotics | UNIV WOLLONGONG (AU) | 2015-02-25 | — | — | EP | disclosed |
| US-8247088-B2 | Emitting complex for electroluminescent devices | GLOBAL OLED TECHNOLOGY LLC (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247088-B2 | Emitting complex for electroluminescent devices | GLOBAL OLED TECHNOLOGY LLC (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120108499-A1 | PEPTOID COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2012-05-03 | — | — | US | disclosed |
| EP-2343285-A2 | Peptoid compounds | UNIVERSITY OF WOLLONGONG (AU) | 2011-07-13 | — | — | EP | disclosed |
| US-20100167995-A1 | PEPTOID COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2010-07-01 | — | — | US | disclosed |
| US-20100052516-A1 | EMITTING COMPLEX FOR ELECTROLUMINESCENT DEVICES | GLOBAL OLED TECHNOLOGY LLC | 2010-03-04 | — | — | US | disclosed |
| US-20100052516-A1 | EMITTING COMPLEX FOR ELECTROLUMINESCENT DEVICES | GLOBAL OLED TECHNOLOGY LLC | 2010-03-04 | — | — | US | disclosed |
| US-7612036-B2 | Peptoid compounds | UNIVERSITY OF WOLLONGONG (AU) | 2009-11-03 | — | — | US | disclosed |
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | PLE PATRICK | 2009-02-05 | — | — | US | disclosed |
| US-20090036485-A1 | Quinoline derivatives | JUNG FREDERIC HENRI | 2009-02-05 | — | — | US | disclosed |
| EP-1412336-A4 | PEPTOID COMPOUNDS | UNIV WOLLONGONG (AU) | 2007-08-29 | — | — | EP | disclosed |
| EP-1802603-A1 | QUINOLINE DERIVATIVES | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| US-20070111927-A1 | Peptoid compounds | UNIVERSITY OF WOLLONGONG (AU) | 2007-05-17 | — | — | US | disclosed |
| US-7160854-B2 | Binaphthyl peptidomimetics for treating vancomycin resistant Staphylococcus aureas infections | UNIVERSITY OF WOLLONGONG (AU) | 2007-01-09 | — | — | US | disclosed |
| WO-2006040522-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| US-20050043509-A1 | Peptoid compounds | UNIVERSITY OF WOLLONGONG | 2005-02-24 | — | — | US | disclosed |
| EP-1412336-A1 | PEPTOID COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003002545-A1 | PEPTOID COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108499-A1 | PEPTOID COMPOUNDS | VIP, FPR1, VIPR1 | ROCK1 2588/4885POLB 1806/4885HTT 3750/4885 |
| US-20100167995-A1 | PEPTOID COMPOUNDS | VIP, FPR1, VIPR1 | ROCK1 2588/4885POLB 1806/4885HTT 3750/4885 |
| US-20090036485-A1 | Quinoline derivatives | AQP3, PGF, AQP1 | ROCK1 492/4885POLB 1189/4885HTT 887/4885 |
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | AQP3, AQP1, F12 | ROCK1 281/4885POLB 2260/4885HTT 3230/4885 |
| US-20070111927-A1 | Peptoid compounds | VIP, FPR1, VIPR1 | ROCK1 2588/4885POLB 1806/4885HTT 3750/4885 |
| US-20050043509-A1 | Peptoid compounds | VIP, FPR1, VIPR1 | ROCK1 2588/4885POLB 1806/4885HTT 3750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.